Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 (KIR3DL1)
- Target
- KIR3DL1
- Molecular classification
- Receptor, Immunoglobulin superfamily, Membrane protein
01
Overview
Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 (KIR3DL1) is a member of the KIR (killer-cell immunoglobulin-like receptor) family, expressed mainly on natural killer (NK) cells and some T cells. It is an inhibitory receptor with three extracellular immunoglobulin-like domains and a long cytoplasmic tail containing immune tyrosine-based inhibitory motifs (ITIMs). KIR3DL1 recognizes specific HLA class I molecules and regulates NK cell function by inhibiting cytotoxic activity, playing a crucial role in innate immune surveillance and self-tolerance. Polymorphism in KIR3DL1 and its ligands influences susceptibility to and progression of cancer, infections, and immune-mediated diseases[1][2][4].
- Other names
- AMB11CD158e1cl-2cl-11KIRnkat3NKB1NKB1B
02
Mechanism of action
Inhibition of NK cell cytotoxicity via immune tyrosine-based inhibitory motifs (ITIMs) upon binding to HLA class I ligands
03
Biological functions
Immune responseRegulation of natural killer cell (NK cell) activitySignal transduction (inhibitory receptor)
04
Disease associations
CancerInfectionInflammationOther (autoimmune and transplant-related diseases)
05
Safety considerations
Potential for immune modulation resulting in undesired immunosuppression or autoimmunityRisk of transplant rejection or tolerance outcomes based on KIR/HLA genotype
Beyond the preview
Go deeper on Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 (KIR3DL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 (KIR3DL1).